timothy sykes logo

Stock News

Humacyte Shares Plunge Amid New Offering

Ellis HobbsAvatar
Written by Ellis Hobbs Reviewed by Jack Kellogg Fact-checked by Tim Sykes
Updated 3/26/2025, 9:19 am ET 3/26/2025, 9:19 am ET | 5 min 5 min read
Humacyte Shares Plunge Amid New Offering Thumbnail

Humacyte Inc.’s stock experienced significant downturn due to news of slashed funding in their latest venture alongside concerns about regulatory scrutiny on Wednesday, Humacyte Inc.’s stocks have been trading down by -28.7 percent.

Share Offering Details

  • A public offering for Humacyte has been announced, with the objective of raising funds. TD Cowen, Barclays, and BTIG will manage this offering.
  • The offering has been priced at $2.00 per share, a significant dip from the previous closing price.
  • An additional 15% of shares may be allotted to underwriters, providing them more leverage if required.

Candlestick Chart

Live Update At 09:18:45 EST: On Wednesday, March 26, 2025 Humacyte Inc. stock [NASDAQ: HUMA] is trending down by -28.7%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Funding Future Ventures

The main goal of this share offering is to support the commercialization of Humacyte’s SYMVESS product. Part of the proceeds will also aid in future product development and meet corporate financial requirements. As millionaire penny stock trader and teacher Tim Sykes, says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.” This approach aligns with our strategy to build assets steadily rather than seeking immediate rewards. The completion of the offering is contingent on favorable market conditions.

More Breaking News

Humacyte’s Financial Snapshot

Stock Performance Trends

Recent figures reflect a downward trend for the stock with a notable drop from its highs earlier. Beginning the week at $3.35, the stock slipped to close nearly 24% lower due to the recent offering announcement, as the market responded to potential dilution risks. Additionally, recent intra-day trading activity indicated heightened volatility, characterized by swift changes in stock price early in the trading day.

Revenue and Profitability

Humacyte’s financial statement provides a tapestry of the company’s current fiscal health. A pre-tax profit margin of -8,179% paints a challenging picture. Despite such numbers, the commitment to forward high-growth initiatives like SYMVESS provides a beacon of potential recovery and success.

Cash Flow and Financing

The firm’s financial documents reveal negative changes in cash flow amounting to nearly -$23M coupled with considerable amounts set aside for operational expenses. Humacyte’s allocation towards continuing investing activities signifies a focus on future growth rather than short-term profitability. The balance of investing strategically in research while managing expenses remains as a recurring theme in Humacyte’s strategy.

Looking to the Horizon: Possible Impacts

The Capabilities of SYMVESS

The SYMVESS product, designed to address vascular trauma, stands out as a critical asset for Humacyte. With significant resources dedicated towards its successful commercialization, SYMVESS is a game-changer. Successful launch and integration into market practices could greatly bolster Humacyte’s brand, subsequently easing pressure from income statement figures.

Market’s Response and Sentiment

The market’s lowered confidence, stirred by stock offering announcements, has ushered in a temporary slide in stock values. However, the potential dilution due to the increase in shares may be offset by the positive impact generated by new advancements in technology and product development outcomes.

Conclusion

Humacyte’s commitment to innovation is evident amidst its current financial hurdles. Traders’ cautious stance is a response to the dilution potential of the share offering, yet the long-term outlook holds promise if the firm successfully executes its product strategy around SYMVESS. As millionaire penny stock trader and teacher Tim Sykes says, “You must adapt to the market; the market will not adapt to you.” This philosophy underscores the importance of Humacyte’s ability to navigate the evolving market environment. Looking toward the future, the ability to capture market share, solidify distribution channels, and uphold a sustainably profitable model remains at the core of watchers’ anticipations for Humacyte.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Ellis Hobbs

Trainer and Mentor on Tim Sykes’ Trading Challenge
He teaches webinars on Tim Sykes’ Trading Challenge He treats trading like a business, not a hobby He emphasizes taking small risks — “If you get the process right, money is a forgone conclusion.”
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”